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Abstract
The human body is critically dependent on the ventilatory control system for adequate uptake of oxygen
and removal of carbon dioxide (CO2). Potent opioid analgesics, through their actions on m-opioid
receptor (MOR) expressed on respiratory neurons in the brainstem, depress ventilation.Opioid-induced
respiratory depression (OIRD) is potentially life threatening and the cause of substantial morbidity and
mortality. One possible way of prevention of OIRD is by adding a respiratory stimulant to the opioid
treatment, which through activation of non-opioidergic pathways will excite breathing and consequently
will offset OIRD and should not affect analgesia. Various new respiratory stimulants are currently under
investigation including (a) potassium channel blockers acting at the carotid bodies, and (b) ampakines and
(c) serotonin receptor agonists acting within the brainstem. (a) GAL-021 targets BKCa-channels. Initial
animal and human experimental evidence indicates that this potassium channel blocker is a potent
respiratory stimulant that reverses OIRD without affecting antinociception. GAL021 is safe and better
tolerated than the older K+-channel blocker doxapram and more efficacious in its effect on respiration.
(b) Ampakines modulate glutamatergic respiratory neurons in brainstem respiratory centers. Various
ampakines have been studied showing their ability to increase respiratory drive during OIRD by
increasing respiratory rate. Currently, CX717 is the most promising ampakine for use in humans as it is
safe and does not affect opioid analgesia. (c) While animal studies show that serotonin receptor agonists
increase respiratory drive via activation of serotonin receptors in brainstem respiratory centers, human
studies are without success. Further clinical studies are required to improve our care of patients that are
treated with potent opioid analgesics. The use of non-opioid adjuvants may reduce the probability of
OIRD but does never relieve us of our duty to continuously monitor these patients, irrespective whether
they are treated in-house or in an ambulatory setting.
The ventilatory control system and opioid-induced
respiratory depression
Humans are critically dependent on the cardiorespiratory
control system for adequate uptake of oxygen and
removal of CO2 via the lungs [1]. Ventilation is
controlled by two systems: the chemical or metabolic
control of breathing and the behavioral control system.
The behavioral control system is active during wakeful-
ness and rapid-eye-movement sleep and allows the
adjustment of breathing to specific circumstances and
needs such as speaking, eating, reading, surprise, anxiety,
and pain. Several brain areas, including the cortex, limbic
system, and hypothalamus, are involved in the beha-
vioral control system. The chemical control system is
dependent on the chemical composition of arterial blood
and cerebrospinal fluid — most importantly, pH, CO2
partial pressure (pCO2), and oxygen partial pressure
(pO2) — and relies on a set of chemosensors in the
brainstem (central chemoreceptors) and in the carotid
bodies (peripheral chemoreceptors) [2]. Deviations from
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chemical cellular homeostasis will result in compensa-
tory mechanisms, primarily by adaptations in breathing
frequency and tidal volume. For example, acidosis and
hypoxia will activate specific chemosensitive cells in the
chemoreceptors, causing a hyperventilatory response
aimed at restoration of pO2 and pCO2 toward normoxic
(arterial pO2 of 95 to 110mmHg) and normocapnic (38
to 42 mm Hg) values, respectively. The two control
systems interact in a complex fashion and come together
in multiple respiratory centers in the brainstem, where
the drive to breathe is generated (Figure 1). A variety of
different receptors are expressed on respiratory neurons,
Figure 1. Simple schematic representation of the ventilatory control system
Information from peripheral and central chemoreceptors, the lungs and higher brain centers is integrated in brainstem respiratory centers, which through
efferent pathways control motor neurons of the diaphragm and other respiratory muscles so that breathing is adapted to both metabolic and behavioral
needs.
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and their activation or inhibition will directly affect
breathing [1]. Depending on the circumstances, this may
be advantageous (specific receptor agonists/antagonists
may beneficially influence our breathing) or disadvanta-
geous (specific drugs may depress ventilation, causing
potentially fatal conditions).
In current medical practice, the most important group of
drugs that depress ventilation are opioids, which include
both the natural derivatives from the poppy plant, Papaver
somniferum (opiates such as morphine), and (semi)
synthetic opioids (the fenylpiperidines such as fentanyl,
sufentanil, alfentanil, and remifentanil and others such as
buprenorphine, oxycodone, andmethadone) [3]. Opioids
are used to treat acute and chronic pain (inside and
outside of the hospital setting) and play an important role
in palliative care. In patients receiving high-dose opioids
in the community for the treatment of non-malignant
pain, inadvertent overdose or addiction is amajor cause of
morbidity and mortality [4]. Furthermore, these prescrip-
tion opioids often change hands, resulting in misuse and
abuse outside of the medical setting with casualties from
overdose or dangerous drug combinations (for example,
opioids combined with sedatives, alcohol). Currently,
more individuals die from prescription opioids than from
illicit drugs (for example, heroin and cocaine). In the US,
the number of prescription opioid overdose deaths
increased from 4,400 in 1999 (12 individuals per day)
to 16,000 in 2010 (44 individuals per day) [5]. Over this
same period, there were similar increases in opioid sales
(more than 4 million Americans per year receive long-
acting or prolonged-release opioids for treatment of
chronic pain) and admissions in opioid-abuse treatment
centers (>400%) [5]. The rise in opioid prescriptions in the
US is partly related to the increased awareness of clinicians
to diagnose and treat chronic pain, to the increase in the
number of opioid formulations being marketed, and to
the pressure from the industry on physicians to prescribe
opioids [6]. Although we have a good idea of the number
of individuals who die from prescription opioids, the
number of near-fatal events remains unknown. Our
educated guess is that non-fatal respiratory events from
prescription opioids exceed fatal events by at least a factor
of 100. In agreement with the data from the community,
parenteral opioids in the clinical setting are considered a
major and independent risk factor for development of
cardiorespiratory arrest [7–9].
The main cause of opioid fatalities is cardiorespiratory
arrest initiated by OIRD with subsequent hypoxia and
hypercapnia [1,3,7–9]. OIRD is directly related to the
activation of opioid receptors expressed on respiratory
neurons in the central nervous system. Since opioid
receptors are abundant in brainstem respiratory centers
[10], various opioid-related effects are observed: depres-
sion of the ventilatory responses to hypercapnia and
hypoxia, depression of ventilation (related to reductions
in respiratory rate and volume) and the wakefulness
drive to breathe, irregular breathing, suppression of
pharyngeal muscle (including the tongue) function, and
depression of the arousal response. Various patterns of
OIRD may be observed, depending on multiple factors,
including the physicochemical properties of the opioid
(responsible for the drug’s kinetics and dynamics),
opioid dose, route of administration, speed at which
the opioid concentration rises at its site of action (for
example, a slow rise enables the patient to accumulate
CO2 which offsets OIRD [11]), underlying disease (for
example, recurrent hypoxic events enhance opioid
sensitivity [12,13]), inspired oxygen concentration (a high
fraction of inspired oxygen [FiO2] enhances OIRD –
Figure 2) [14], genetics, and gender. The clinical picture
that emerges is related to complex interactions with brain
sites involved in arousal, nociception, nausea/vomiting,
and so on. Some patterns of OIRD are dominated by
superficial ventilation, reduced respiratory rates, and
eventually central apnea; others by cyclic breathing and
obstructive events.
In light of the above, an import question is how to prevent
OIRD. Various solutions come to mind. One possibility is
to develop analgesics that rely on their analgesic effect by
acting at opioidergic and non-opioidergic pathways
simultaneously. One such drug is tapentadol [15], which
is an MOR agonist (with a weaker affinity for the MOR
than morphine) and noradrenaline re-uptake inhibitor.
Tapentadol produces potent analgesia due to analgesic
synergy from its two mechanisms of action. Theoretically,
tapentadol would produce limited respiratory depression.
However, no studies on the respiratory effects of
tapentadol are currently available. Another possibility
would be to add a respiratory stimulant to the opioid,
which through activation of non-opioidergic pathways
will excite breathing and consequently offset OIRD. It is
important that these adjuvants not affect analgesia.
Respiratory stimulants used in the last four or five decades
include CO2, doxapram, almitrine, acetazolamide, theo-
phylline, and caffeine. Whereas some of these are still in
use today, none has been developed to treat OIRD and
most come with side effects that limit their clinical use
[16]. Currently, novel drugs are being developed or
investigated (or both) to treat OIRD specifically [1].
These agents will be discussed below.
These non-opioid adjuvants are different from naloxone,
which is an opioid receptor antagonist and restores
breathing by its antagonist effect at the MOR [1,17].
Naloxone is used to treat OIRD; however, owing to its
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mechanistic pathways, it will reduce or abolish opioid
analgesia as well. An additional drawback of naloxone is its
short half-life (its elimination half-life is 15 to 20 minutes
[17]). Therefore, a single naloxone bolus injection may be
followed by “re-narcotization” (that is, the return of OIRD
following a [short] period of adequate ventilation,
potentially putting the patient’s life further at risk,
especially when long-acting or high-dose opioids are the
cause of OIRD).
Reversal of opioid-induced respiratory
depression by non-opioids
Respiratory stimulants that act through non-opioid
receptor systems are of real therapeutic benefit as they
may restore breathing to an acceptable level or even
prevent OIRD without affecting analgesia. Three drug
classes will be discussed: potassium channel blockers,
ampakines, and 5-hydroxytryptamine (serotonin, 5HT)
receptor agonists.
Potassium channel blockers
The oldest (available since the 1960s) and best known K+-
channel blocker that stimulates breathing is doxapram.
Doxapram inhibits background K+ channels (TASK1,
TASK3, and the TASK1/3 heterodimer) on type 1 carotid
body cells [18,19]. The channels mediate background
“leak” K+ current, thereby regulating neuronal excitability
[18,19]. TASK-channel antagonism by doxapram produces
Figure 2. Opioid-induced respiratory depression following a 50 mg intravenous bolus dose of remifentanil in one person during air
breathing (left) and during inspiration of 50% oxygen in N2
(A, B) Breath-to-breath ventilation in L/min. (C, D) Breathing frequency. (E, F) Oxygen saturation. The green syringes indicate opioid administration. The
red data indicate artificial mask ventilation. Data from [11] with permission. Abbreviations: bpm, breaths per minute.
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respiratory stimulation [20]. However, doxapram comes
with many side effects, including anxiety/panic attacks,
sympathoexcitation, sweating, and convulsions [16].
Cardiovascular stimulation causes hypertension and
increases cardiac output. This is not without conse-
quences. For example, we recently showed that the
doxapram-induced increase in cardiac output was asso-
ciated with reduced plasma concentrations of the opioid
alfentanil [21]. This evidently will reduce OIRD but also
analgesia. In the rat, Cotten [19] investigated the effect of
PK-THPP and A1899, potent potassium-channel blockers
that act selectively as TASK1 and TASK3 antagonists. He
showed that both agents produced greater respiratory
stimulation than doxapram but with little effect on blood
pressure. To the best of our knowledge, no studies have
been done in humans.
GAL-021 is a novel developed K+-channel blocker,
blocking BKCa channels (large-conductance Ca
2+/voltage-
activated K+ channels) [22]. Initial evidence that GAL-021
is a respiratory stimulant acting predominantly at the
carotid bodies and reverses OIRD without affecting
antinociception comes from animal studies [16]. For
example, the efficacy of GAL-021 is severely abolished in
carotid body resected animals and in mice lacking
essential subunits of the BKCa channel. Phase 1 human
studies show that GAL-021 is safe and indeed acts as a
potent respiratory stimulant [23]. We recently assessed the
effect of GAL-021 on alfentanil-induced respiratory
depression (alfentanil plasma concentrations of 40 and
100 ng/mL) in healthy volunteers and observed that
GAL-021 at plasma concentrations ranging from 400 to
1200 ng/mL increases opioid-depressed ventilation
(Figure 3) [24,25]. Important additional observations
from our study were that GAL-021 does not reduce
analgesia and that it has no effect on sedation, cardiac
output, or bloodpressure. Furthermore, a pharmacokinetic-
pharmacodynamic analysis of the data revealed that
GAL-021 has a rapid onset time/offset time (blood-effect-
site equilibration half-life of less than 0.5 minutes),
making this drug an attractive alternative to naloxone
(M. Roozekrans, unpublished observation). Further studies
will be needed to assess the full dose-response relationship
at higher opioid and higher GAL-021 dosages and
consequently more severe respiratory depression.
Ampakines
Ventilatory drive may be modulated by manipulation of
glutamatergic and serotonergic neurotransmission in
respiratory centers in the brainstem (Figure 1) [26]. An
important respiratory area identified in animals is the
pre-Bötzinger complex, which is involved in respiratory
rhythm generation [27]. The pre-Bötzinger complex is
part of the ventral respiratory group or column [28].
Animal studies show that ampakines increase respira-
tory rate by their action at amino-3-hydroxy-5-methyl-
D-aspartate (AMPA) receptors in the pre-Bötzinger
complex. In published studies, various ampakines have
shown their ability to increase respiratory drive during
OIRD (by increasing respiratory rate and the slope of the
ventilatory response to CO2) [29-31]. The most promis-
ing ampakine is CX717. It is safe for use in humans and
is available for treatment of attention deficit hyperactiv-
ity disorder and Alzheimer’s disease. In humans, CX717
prevents alfentanil-induced respiratory depression
without affecting analgesia, although sedation tended
to increase [31]. In this study, the volunteers were
pre-treated with the ampakine, which allows prevention
of OIRD but not treatment of established OIRD, and no
opioid dose-response data were presented. Hence,
further (dose-response) studies are required to give a
critical appraisal of this therapy and assess whether
CX717 is clinically useful in the prevention of OIRD.
Possibly, these drugs may prove useful to prevent non-
opioid-induced respiratory depression such as reduced
ventilation from propofol [32]. To the best of our
knowledge, no further human studies are currently
performed with CX717 (search of ClinicalTrials.gov
Figure 3. Effect of GAL-021 on alfentanil-induced respiratory
depression in one person
The bottom graph depicts the increase in ventilation during alfentanil infusion
(plasma concentration kept constant at 50 mg/mL) following low- and high-dose
GAL-021 (top graph). Low-dose GAL-021 increases ventilation by about
5 L/min, high-dose by 10 to 15 L/min. Data are from refs. [21,22].
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using terms “ampakine” and “respiratory depression” on
1 May 2014).
Serotonin receptor agonists
Animal studies show that serotonin agonists increase
respiratory drive via actions at 5HT1A, 5HT7, and 5HT4a
receptors [1,33]. In human volunteers, these agents were
not successful. For example, the 5HT1A agonist buspir-
one and the 5HT4a agonist mosapride are without effect
on OIRD in humans [34,35]. The lack of efficacy in
humansmay be related to low potency or the lower brain
concentrations achieved in human studies compared
with animal studies. Owing to the appearance of side
effects (for example, nausea/vomiting), higher dosages
are often not possible in humans.
Primum non nocere (above all, do no harm)
OIRD is a serious problem that requires our attention
and a rapid solution. The use of non-opioid adjuvants
such as those discussed above (for example, CX717 or
GAL-021) may reduce the probability of OIRD. In a
recent editorial entitled “Primum non nocere, or How to
resolve drug-induced respiratory depression” [36], we
discussed the various patient populations that may
require treatment with these respiratory stimulants. We
argued that all patients who receive opioid treatment are
at potential risk for OIRD and hence all patients on
opioids may be expected to belong to the target
population for treatment with non-opioid respiratory
stimulants, although actual treatment possibilities will
depend on the available formulations. Furthermore, in
three analyses of case reports on OIRD published since
1980, it became apparent that in a large number of cases
neither specific patient factors nor specific case-related
factors dominate the general picture of OIRD [37–39].
This indicated that a priori prediction of OIRD is difficult
if not impossible. Various options may be considered to
reduce the probability of OIRD, such as by (a) reducing
opioid dose by adding opioid-sparing medication,
(b) restricting the prescription of opioids in the ambulatory
setting to well-trained specialists as may be found in
specialist pain clinics, and (c) exercising caution in opioid
prescription by applying strict opioid titration rules in
opioid-naïve patients. Furthermore, as we previously stated
[36], even with appropriate respiratory stimulants on
board, the risk of OIRD does not vanish and hence we
have to additionally apply optimal patient monitoring for
patients who are treated in-house as well as those treated in
the ambulatory setting. An example of a possibly useful
monitor that is used in the clinical setting is the Integrated
Pulmonary Index™ (IPI, Covidien, Mansfield, MA) that
integrates four measurements (pulse rate, end-tidal CO2,
oxygen saturation, and respiratory rate) by applying a fuzzy
logic algorithm to come up with a real-time index
ranging from 1 (the patient requires immediate attention)
to 10 (“normal” condition). The IPI has been tested in
postoperative adult patients and pediatric patients during
deep sedation [40,41]. In both studies, the IPI gave an
adequate indication of the respiratory status of the patient.
Further studies are required to assess whether the IPI is less
noise-sensitive than commonly used respiratory monitors,
which are known to cause repetitive false alarms and
consequently alarm fatigue [42]. For the ambulatory
(community) setting, there is the need for the development
of a small and inexpensive intelligent monitor that
continuously and accurately senses and monitors the
cardiovascular and respiratory state of the patient. Cur-
rently, such a monitor is not available.
Abbreviations
5-HT, 5-hydroxytryptamine (serotonin); CO2, carbon
dioxide; IPI, Integrated Pulmonary Index™; MOR, m-
opioid receptor; OIRD, opioid-induced respiratory
depression; pCO2, carbon dioxide partial pressure;
pO2, oxygen partial pressure.
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